Brazilian Health Regulator Approves “Exceptional Import” Of Four Million Doses Of Bharat Biotech’s CovaxinBharat Biotech’s COVAXIN, India’s first indigenous vaccine against coronavirus. (Swarajya Magazine)

In a boost for India's maiden indigenously developed COVID-19 vaccine, Brazilian health regulator Anvisa has given the nod to "exceptional import" of Hyderabad-based Bharat Biotech's Covaxin, reports Times of India.

It should be noted that as per a loosely translated version of Anvisa's announcement, the body has given the approval for an initial four million doses of Covaxin for distribution and use "under controlled" and specific conditions.

Upon the use of these four million doses, Anvisa will analyse the data to assess the further quantities of Covaxin to be imported.

It should be noted that back in March, Anvisa had turned down the first import request made by the Brazilian Health Ministry. After this, the Ministry approached Anvisa again in May. Bharat Biotech had also approached Anvisa in May end seeking approval for two Good Manufacturing Practices (GMP) implemented by it.

In this light, announcing the approval for Covaxin, Anvisa took note of the improvements made in the manufacturing line at Bharat Biotech's facility in India.

An Appeal...

Dear Reader,

As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.

Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.

We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.

Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.

Become A Patron
Become A Subscriber